Clinical trials: Flu Vaccine
Tetanus, Diphtheria
Confirmatory Study of BK1310 in Healthy Infants
The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with…
- Conditions
- Tetanus, Diphtheria, Pertussis, Poliomyelitis
- Trial name
- NCT03891758
- Testing
- DPT-IPV-Hib, Hib vaccine, DPT-IPV
- Where
- Japan
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Influenza, Human
Tropical Influenza Control Strategies for the Elderly
TROPICS1 is a randomized, observer-blind, active comparator-controlled, single-center, Phase IV trial in 200 participants aged ≥65 years.
- Trial name
- TROPICS1 (NCT02655874)
- Testing
- Influenza vaccine, Tetanus-diphtheria-pertussis vaccine
- Where
- Singapore
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
Influenza, Virus Diseases
Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults
UMN-0501 is a purified recombinant influenza HA vaccine (A H5N1/Vietnam/1203/2004). The purpose of the present study is to evaluate immunogenicity, safety and optimal dose among three different doses of UMN-0501 following two…
- Trial name
- NCT00980447
- Testing
- UMN-0501
- Where
- 2 sites in Japan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Immunization; Infection|Transplantation Infection|Influenza, Influenza
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center.
- Trial name
- NCT07192458
- Testing
- Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt University Medical Center
Influenza
Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults
A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over. To assess the effect of MVA-NP+M1 on the reduction of laboratory confirmed influenza when given as an adjunct…
- Trial name
- NCT03880474
- Testing
- MVA-NP+M1, Saline
- Where
- 9 sites in Australia
- Volunteers
- 2,364 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Pneumococcal Vaccines
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit…
- Trial name
- NCT07365826
- Testing
- 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok)
- Where
- 25 sites in United States
- Volunteers
- 1,390 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Respiratory Synctial Virus Infections
Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults
The aim of the study is to investigate immunogenicity and safety of the RSV/Flu-01E intranasal vaccine for the prevention of respiratory syncytial virus infection in volunteers over 60 years
- Trial name
- NCT06890429
- Testing
- RSV/Flu-01E
- Where
- 3 sites in Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Research Institute of Influenza, Russia
Influenza Vaccine
Preliminary Safety Assessment of a Quadrivalent Subunit Influenza Vaccine in China
This study evaluates the safety of the quadrivalent subunit influenza vaccine in individuals aged 3 years and older in Jiangsu Province, China.
- Trial name
- NCT07710586
- Testing
- quadrivalent subunit influenza vaccine
- Where
- 2 sites in China
- Volunteers
- 3,105 people, healthy volunteers welcome
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
HIV-1 Infection, H1N1
Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth
The purpose of this research study is to evaluate the immune response to the H1N1 influenza or "flu" vaccine. The "immune response" is how your body recognizes and defends itself against bacteria, viruses, and substances that may…
- Conditions
- HIV-1 Infection, H1N1, Influenza, Flu
- Trial name
- NCT01484522
- Testing
- FluMist, Fluvirin, Fluzone
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 149 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Inactivated Influenza Vaccine
Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age
Study of the safety and immunogenicity (antibody producing capability) comparing inactivated influenza vaccine to placebo given to infants at 2 and 3 months of age.
- Trial name
- GRC28 (NCT00242424)
- Testing
- 2005-2006 trivalent inactivated influenza vaccine
- Where
- United States
- Volunteers
- 1,375 people, healthy volunteers welcome
- Sponsor
- Seattle Children's Hospital
Transplant
Immune Response to Influenza Vaccine in Islet Cell Transplant Recipients
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for organ transplant patients, studies have shown…
- Trial name
- NCT01149382
- Where
- Canada
- Volunteers
- 61 people
- Sponsor
- University of Alberta
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults
This study is designed to test the immunogenicity in terms of Hemagglutination Inhibition (HI) antibodies against each of the three vaccine influenza strains and reactogenicity and safety of Fluviral® containing the influenza…
- Trial name
- NCT01626820
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Prevention, Seasonal Influenza
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
Background: Vaccines help the body learn to fight infections. Some vaccines are combined with adjuvants, which are added substances that make vaccines work better.
- Trial name
- NCT06863142
- Testing
- VRC-FLUMOS0116-00-VP, ALFQ
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Pregnancy
Influenza Vaccine in Pregnancy Part 2
Pregnant women have limited knowledge regarding influenza, its implications during pregnancy, and recommendations for vaccination during pregnancy.
- Trial name
- NCT00593970
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Influenza
The Interaction Between Mucosal Microbiota Colonization and the Immune Response to an Intranasal Influenza Live Attenuated Vaccine
This is a single-center, randomized, open-label trial designed to explore the interaction between mucosal microbiota colonization in the nasal cavity and gut and the immune response to an intranasal live attenuated influenza…
- Trial name
- NCT06609811
- Testing
- Intranasal Influenza Live Attenuated Vaccine
- Where
- China
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza, Infections, Pneumococcal
System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts
The goal of this research study is to improve rates of appropriate influenza and pneumococcal vaccination among adults who receive care at a large multi-specialty group practice in central Massachusetts.
- Trial name
- NCT02266277
- Testing
- Arm 1: E-portal message with IVR call, Arm 2: E-portal message with no IVR call, Arm 3: No e-portal message with IVR call
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- University of Massachusetts, Worcester
Influenza
Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months
This phase IV protocol is designed to evaluate the safety, clinical tolerability and immunogenicity of the 2005-2006 formulation of three widely used conventional influenza vaccines in children aged 6 to 35 months
- Trial name
- NCT00311428
- Testing
- Influenza
- Where
- Finland
- Volunteers
- 270 people
- Sponsor
- Novartis
Seasonal Influenza B
Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults
This is a phase 1, single-center, placeb-controlled, double-blind study. The purpose of this study is to determine the safety and immunogenicity of an oral vaccine tablet to prevent seasonal influenza B tested at two dose levels…
- Trial name
- NCT02547792
- Testing
- VXA-BYW.10 (Low Dose) Oral Vaccine, VXA-BYW.10 (High Dose) Oral Vaccine
- Where
- New Zealand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Vaxart
Avian Influenza, Influenza Immunisation
2017 A/H7N9 IIV Revaccination
This is a Phase II clinical trial in up to 420 males and non-pregnant females, 19 to 70 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03738241
- Testing
- A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent
- Where
- 9 sites in United States
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
The hypothesis for this trial is that the incidence of a pre-defined composite of common systemic hypersensitivity adverse events for Flublok recipients is non-inferior to that reported for licensed IIV recipients.
- Trial name
- NCT01825200
- Testing
- Flublok, Afluria
- Where
- 14 sites in United States
- Volunteers
- 2,640 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.